Antibiotic prophylaxis and open groin hernia repair

Area of Science:

• Surgical Infection Prevention
• Clinical Trials
• Hernia Repair Outcomes

Background:

• Antibiotic prophylaxis is not standard for clean, non-implant surgeries, but this practice is increasingly debated.
• Evidence supporting routine antibiotic use in specific clean surgical procedures remains inconclusive.

Purpose of the Study:

• To evaluate the efficacy of co-amoxiclav as antibiotic prophylaxis in preventing surgical site infections (SSIs) after open groin hernia repair.
• To compare outcomes between patients receiving co-amoxiclav and those receiving a placebo.

Main Methods:

• A randomized, multicenter, double-blind, placebo-controlled trial involving 619 patients undergoing open groin hernia repair.
• 563 patients completed the study, with 283 assigned to co-amoxiclav and 280 to placebo.
• Data collected included anesthetic type, repair technique, wound closure, and post-operative complications, with a 6-week follow-up.

Main Results:

• The overall incidence of wound infection was 8.9% (50 patients).
• There was no statistically significant difference in wound infection rates between the co-amoxiclav group (25 infections) and the placebo group (25 infections).
• No significant differences were observed in other patient characteristics or surgical variables between the two groups.

Conclusions:

• Antibiotic prophylaxis with co-amoxiclav does not reduce the incidence of wound infections in patients undergoing open groin hernia repair.
• Current evidence suggests that routine antibiotic prophylaxis is not beneficial for this specific surgical procedure.
• Further research may be needed to identify specific patient subgroups who might benefit from prophylactic antibiotics.